Top 300 Pharmacy Drug Cards

ENALAPRIL: Vasotec, Various

Class: ACE-I, Antihypertensive

Dosage Forms. Tablet: 2.5 mg, 5 mg, 10 mg, 20 mg

Image

Common FDA Label Indication, Dosing, and Titration.

1. CHF: Children 4 d and older, 0.1-0.5 mg/kg po daily, max 0.94 mg/kg po daily; Adults, 2.5 mg po daily or bid, max 40 mg po daily in divided doses

2. Hypertension: Children 6-16 y, 0.08 mg/kg up to 5 mg po daily, max 0.58 mg/kg or 40 mg po daily; Adults, 5 mg po daily, max 40 mg po daily in divided doses

3. Kidney disease, nondiabetic: Children 7-18 y, 0.1-0.5 mg/kg po daily, max 20 mg po daily; Adults, 5 mg po daily, max 20 mg po daily

Off-Label Uses.

1. Diabetic nephropathy: 5-20 mg po daily

2. MI: 2.5 mg po daily, may titrate to 20 mg po daily

MOA. Enalapril is a prodrug that is rapidly converted to its active metabolite, enalaprilat, a competitive ACE inhibitor. It reduces serum aldosterone, leading to decreased sodium retention, potentiates the vasodilator kallikrein–kinin system, inhibits the sympathetic nervous system, and inhibits the tissue renin–angiotensin system. The net effect is reduction in total peripheral resistance and blood pressure in hypertensive patients, and reduction of elevated afterload in patients with CHF.

Drug Characteristics: Enalapril

Image

Medication Safety Issues: Enalapril

Image

Drug Interactions: Enalapril

Image

Adverse Reactions: Enalapril

Image

Efficacy Monitoring Parameters. Decreased BP, signs of CHF.

Toxicity Monitoring Parameters. Signs of angioedema (swelling of the face, eyes, lips, tongue, or throat), severe persistent cough, hypotension; monitor baseline and periodic electrolytes, SCr, BUN, and urine protein.

Key Patient Counseling Points. Use potassium supplements or salt substitutes only under medical supervision.

Clinical Pearls. Progressive renal impairment including acute renal failure may occur on enalapril therapy. Injectable formulation, enalaprilat, also available. Injectable and oral dosing not interchangeable.